RT Journal Article
T1 Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis.
A1 Rojas-Gimenez, Marta
A1 Lopez-Medina, Clementina
A1 Calvo-Gutierrez, Jerusalem
A1 Puche-Larrubia, Maria Angeles
A1 Gomez-Garcia, Ignacio
A1 Segui-Azpilcueta, Pedro
A1 Abalos-Aguilera, Maria Del Carmen
A1 Ruiz, Desiree
A1 Collantes-Estevez, Eduardo
A1 Escudero-Contreras, Alejandro
K1 Biological therapy
K1 Cardiovascular risk
K1 Rheumatoid arthritis
K1 Subclinical atherosclerosis
AB The objective of this study was to assess the association of carotid intima-media thickness (CIMT), and also the presence of atheromatous plaque, with biological and targeted synthetic disease-modifying antirheumatic drugs, in an established cohort of patients with rheumatoid arthritis (RA). We conducted a cross-sectional observational study based on a cohort of patients with RA and a registry of healthy controls, in whom the CIMT and presence of atheromatous plaque were assessed by ultrasound. Data were collected on disease activity, lab results and treatments. Descriptive and bivariate analyses were performed and two multivariate linear regression models (with CIMT as the dependent variable) were constructed to identify variables independently associated with CIMT in our sample of patients with RA. A total of 176 individuals (146 patients with RA and 30 controls) were included. A higher percentage of patients than controls had atheromatous plaque (33.8% vs. 12.5%, p = 0.036), but no differences were found in terms of CIMT (0.64 vs. 0.61, p = 0.444). Compared to values in patients on other therapies, the CIMT was smaller among patients on tumour necrosis factor alpha (TNFα) inhibitors (mean [SD]: 0.58 [0.10] vs. 0.65 [0.19]; p = 0.013) and among those on Janus kinase inhibitors (mean [SD]: 0.52 [0.02] vs. 0.64 [0.18]; p  The use of TNFα inhibitors may protect against subclinical atherosclerosis in patients with RA, patients on this biologic having smaller CIMTs than patients on other disease-modifying antirheumatic drugs. Nonetheless, these results should be confirmed in prospective studies with larger sample sizes.
PB MDPI
SN 2075-4418
YR 2021
FD 2021-12-27
LK http://hdl.handle.net/10668/20956
UL http://hdl.handle.net/10668/20956
LA en
NO Rojas-Giménez M, López-Medina C, Calvo-Gutiérrez J, Puche-Larrubia MÁ, Gómez-García I, Seguí-Azpilcueta P, et al. Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis. Diagnostics (Basel). 2021 Dec 28;12(1):64
DS RISalud
RD Apr 20, 2025